Novartis Boosts Biologics Offering With $300m Investment In European Facilities
The funds will help advance biologic R&D, manufacturing and commercialization capabilities across Europe as the major pursues more sophisticated modalities, its global biologics head tells Scrip.
You may also be interested in...
Tsai and Schaffert out as the Swiss giant looks to maximize returns from its US business, and find more transformational drugs with the help of a new ‘strategy and growth officer’.
Kesimpta is a treatment option for multiple sclerosis patients "that doesn't need compromise, the trade-off between high efficacy and high treatment burden," Novartis neuroscience chief Norman Putzki tells Scrip.
The US firm’s oral plasma kallikrein inhibitor was associated with liver elevations in a number of Phase II patients, prompting a trial termination and shift in focus to an on-demand program.